



Date: 29-04-2020

BSE Limited,  
Market Operations Dept.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Ref : Script Id "BAJAJHCARE", Script Code "539872".**  
**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sirs,

In terms of regulation 30 of SEBI (LODR) Regulation, 2015, this is to inform you that the Company has agreed to acquire stressed Assets from Saraswat Cooperative Bank comprising of Land, Building, Plant & Machineries and other assets as per Annexure "A" subject to completion of closing conditions, by way of cash consideration of INR 610 million subject to closing adjustments.

This disclosure is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Schedule III of the aforesaid regulations and is for your information and record.

Yours faithfully,

**For and behalf of Board of Directors of  
Bajaj Healthcare Limited**

A handwritten signature in black ink, appearing to read 'Aakash', enclosed in a hand-drawn oval.

**Company Secretary  
Aakash Keshari**

**Encl: Annexure "A"**

**BAJAJ HEALTHCARE LIMITED**

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane- 400604  
Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892

**Annexure- A**

**Details of acquisition of Stressed Assets comprises of Land, Building, Plant & Machineries:**

<p>Name of the target entity (details in brief such as size, turnover etc.).</p>	<p>The Company is acquiring only targeted stressed Assets from the Saraswat Cooperative Bank comprises of Plant and Machineries having installed capacity of 111 MT per month and Land, Building, as under:</p> <ol style="list-style-type: none"> <li>1) Land at Tarapur Industrial Area MIDC - Dist Palghar, Maharashtra</li> <li>2) Factory building on above plot</li> <li>3) Vacant Industrial Land - Dahej Industrial Area, GIDC, Bhaaruch, Gujarat and</li> <li>4) Two Vacant Flats at Jogeshwari ( E) Mumbai</li> </ol>
<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length".</p>	<p>The acquisition does not fall within the definition of related party transaction.</p>
<p>Industry to which the entity being acquired belongs.</p>	<p>Basic Drugs and Pharmaceutical Intermediates (API)</p>
<p>Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).</p>	<p>The existing product portfolios of these Assets are highly complementary to the current priorities and future focus of the Company. This transaction will enable the Company to access additional portfolio opportunities going forward and optimize the launches of in pipeline products. We believe that this acquisition will be profitable in long term through a combination of top line growth, margin accretive and building newer synergies and consolidation of company's presence in local API Market.</p>
<p>Brief details of any governmental or regulatory approvals required for the acquisition.</p>	<p>No Regulatory approvals are required except Approval and consent from MIDC and GIDC</p>

**BAJAJ HEALTHCARE LIMITED**



**BAJAJ**

Indicative time period for completion of the acquisition.	Transaction is expected to close by October 2020.
Nature of consideration - whether cash consideration or share swap and details of the same.	This transaction is for all cash consideration.
Cost of acquisition or the price at which the shares are acquired.	The total cash consideration for this transaction (of acquisition of targeted assets) is INR 610 million which will be funded by a combination of internal accruals and long term borrowing, as may be approved by the Board.
Percentage of shareholding / control acquired and / or number of shares acquired.	The Company is only acquiring Assets . No shareholding stake in entity is being acquired by the Company.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	The targeted assets have installed capacity of 111 MT per month and are capable of manufacturing bulk drugs & API products like Mefenamic Acid, Artemether, Lumefranrine, Aceclofenac Albendazole and Nimesulide . These APIs are used in pain management, tapeworm infection and anti malarial drug

**BAJAJ HEALTHCARE LIMITED**

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane- 400604  
Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : [bajajhealth@bajajhealth.com](mailto:bajajhealth@bajajhealth.com)

CIN No. L99999MH1993PLC072892